RT Journal
A1 Blum A, Podovitzky O, Nuri J, Khasin M
T1 EValuating enzyme replacement therapy in fabry disease—reply
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2010
FD March 22
VO 170
IS 6
SP 573
OP 574
DO 10.1001/archinternmed.2010.43
UL http://dx.doi.org/10.1001/archinternmed.2010.43
AB 
Up to 60% of men with classic Fabry disease have cardiac abnormalities, including left ventricular hypertrophy, valvular dysfunction, and conduction abnormalities. Recent data suggest that left ventricular hypertrophy and systolic function improve after 12 months of ERT.1 Systolic function is usually preserved, but mild to moderate impairment of diastolic filling is a relatively common finding, representing probably the most important cause of dyspnea in patients with Fabry disease.2